title: [Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients].
abstract: OBJECTIVE
  To evaluate the pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients.
  
  
  METHODS
  A total of 16 patients were enrolled in the LPV pharmacokinetic study. Blood samples were collected before LPV intake and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0 h after administration. Serum level of LPV was determined by the developed high performance liquid chromatography (HPLC) method. The pharmacokinetic profiles were assessed by WinNonlin software.
  
  
  RESULTS
  The non-compartment model pharmacokinetic (PK) parameters were as follows: the peak time of LPV (T(max)) (3.88 ± 0.23)h, maximum plasma concentration (C(max)) (10.36 ± 3.42) mg/L, minimum plasma concentration (C(min)) (2.18 ± 0.34) mg/L, the 24 h area under plasma-concentration-time curve (AUC0-24) (116.22 ± 15.68) mg · h · L⁻¹, half life (T1/2) (4.5 ± 0.13) h, and clearance rate (CL/F) (3.44 ± 1.34) L/h respectively.
  
  
  CONCLUSIONS
  The pharmacokinetic profiles of LPV in Chinese HIV-1 infected patients demonstrate lower C(min) than those of reported studies, while other parameters are similar. Patients should be educated for compliance based on the narrow gap between C(min) and minimum effect concentration.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Infectious Disease,Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; Email: zhengyinl@hotmail.com.
authors.forename: Zhengyin
authors.initials: Z
authors.lastname: Liu
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Du
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.forename: Taisheng
authors.initials: T
authors.lastname: Li
mesh_terms: D002681:China; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011744:Pyrimidinones; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir